Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis

Journal of Bone and Mineral Research

Volumn 30, Issue 12, 2015, Pages 2179-2187

  Jha, Smita ^a   Wang, Zhong ^b   Laucis, Nicholas ^b   Bhattacharyya, Timothy ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

ANTIRESORPTIVES; BISPHOSPHONATE; EPIDEMIOLOGY; FRACTURE PREVENTION; GENERAL POPULATION STUDIES; OSTEOPOROSIS

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DENOSUMAB; ESTROGEN; PARATHYROID HORMONE[1-34]; BONE DENSITY CONSERVATION AGENT; VITAMIN D;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; EDUCATIONAL STATUS; FEMALE; FEMUR DIAPHYSIS FRACTURE; FEMUR FRACTURE; FEMUR INTERTROCHANTERIC FRACTURE; FEMUR SUBTROCHANTERIC FRACTURE; FOOD AND DRUG ADMINISTRATION; FRAGILITY FRACTURE; GROUPS BY AGE; HIP FRACTURE; HOSPITALIZATION; HUMAN; INCIDENCE; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PREVALENCE; PROXIMAL HUMERUS FRACTURE; TREND STUDY; UNITED STATES; VERY ELDERLY; DRUG EFFECTS; FRACTURE HEALING; HIP FRACTURES; INFORMATION PROCESSING; MALE; MASS MEDIUM; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PUBLIC OPINION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DATA COLLECTION; DIPHOSPHONATES; FEMALE; FRACTURE HEALING; HIP FRACTURES; HUMANS; MALE; MASS MEDIA; MIDDLE AGED; OSTEOPOROSIS; OUTCOME ASSESSMENT (HEALTH CARE); PUBLIC OPINION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VITAMIN D;

EID: 84954074591     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2565     Document Type: Article

References (31)

1. Farley JF, Blalock SJ., Trends and determinants of prescription medication use for treatment of osteoporosis. Am J Health Syst Pharm. 2009; 66 (13): 1191-201.
2. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB,. Incidence and mortality of hip fracture in the United States. JAMA. 2009; 302 (14): 1573-9.
3. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ., Continuing bisphosphonate treatment for osteoporosis-for whom and for how long ? N Engl J Med. 2012; 366 (22): 2051-3.
4. Schilcher J, Michaelsson K, Aspenberg P., Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011; 364 (18): 1728-37.
5. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL., Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62 (5): 527-34.
6. Wysowski DK., Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360 (1): 89-90.
7. Black DM, Delmas P, Eastell R, et al., HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of post-menopausal osteoporosis. N Engl J Med. 2007; 356 (18): 1809-22.
8. Whitaker M, Guo J, Kehoe T, Benson G., Bisphosphonates for osteoporosis-where do we go from here ? N Engl J Med. 2012; 366 (22): 2048-51.
9. Wang Z, Ward MM, Chan L, Bhattacharyya T., Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female Medicare beneficiaries. Osteoporos Int. 2014; 25 (8): 2109-16.
10. Wang Z, Bhattacharyya T., Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res. 2011; 26 (3): 553-60.
11. Wysowski DK, Greene P., Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone. 2013; 57 (2): 423-8.
12. Skeldon SC, Kozhimannil KB, Majumdar SR, Law MR., The effect of competing direct-to-consumer advertising campaigns on the use of drugs for benign prostatic hyperplasia: time series analysis. J Gen Intern Med. 2015; 30 (4): 514-20.
13. Nielsen Company. Bing Overtakes Yahoo as The #2 U.S. Search Engine [Internet]. New York: Nielsen Company; 2010 Sep 14 [cited 2015 Jun 8]. Available from: http://www.nielsen.com/us/en/insights/news/2010/bing-overtakes-yahoo-as-the-2-search-engine.html.
14. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey [Internet]. Rockville, MD: Agency for Healthcare Research and Quality; 2015 [cited 2015 Jun]8. Available from: http://meps.ahrq.gov/mepsweb.
15. HCUP NIS Database Documentation. Healthcare Cost and Utilization Project (HCUP) [Internet]. Rockville, MD: Agency for Healthcare Research and Quality; 2015 [updated 18th July, 2014; cited 2015 Jun 8]. Available from: http://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp
16. Anderson RN, Rosenberg HM., Age standardization of death rates: implementation of the year 2000 standard. Natl Vital Stat Rep. 1998 Oct 7; 47 (3):1-16, 20.
17. Heckbert SR, Cummings SR, Smith NL, Psaty BM., Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008; 168 (8): 826-31.
18. ABC News. Osteoporosis Drugs, Like Fosamax May Increase Risk of Broken Bones in Some Women [Internet]. 2010 Mar 8 [cited 2015 Jun 8]. Available from: http://abcnews.go.com/WN/WorldNews/osteoporosis-drugs-fosamax-increase-risk-broken-bones-women/story?id=10044066.
19. Lane JM., Bisphosphonate use for ≥5 years increased risk for subtrochanteric or femoral shaft fractures. J Bone Joint Surg Am. 2011; 93 (16): 1546.
20. Shane E, Burr D, Ebeling PR, et al., Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25 (11): 2267-94.
21. Shane E, Burr D, Abrahamsen B, et al., Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014; 29 (1): 1-23.
22. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL,. How many women have osteoporosis? JBMR Anniversary Classic. JBMR, Volume 7, Number 9, 1992. J Bone Miner Res. 2005; 20 (5): 886-92.
23. Kanis JA, Johnell O, De Laet C, et al., A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004; 35 (2): 375-82.
24. Leslie WD, O'Donnell S, Jean S, et al., Osteoporosis Surveillance Expert Working Group. Trends in hip fracture rates in Canada. JAMA. 2009; 302 (8): 883-9.
25. Jean S, O'Donnell S, Lagacé C, et al., Osteoporosis Surveillance Expert Working Group. Trends in hip fracture rates in Canada: an age-period-cohort analysis. J Bone Miner Res. 2013; 28 (6): 1283-9.
26. McClung M, Harris ST, Miller PD, et al., Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013; 126 (1): 13-20.
27. Hesse B, Nelson D, Kreps G, Croyle R, Arora N, Rimer B, et al., Trust and sources of health information: the impact of the Internet and its implications for health care providers: findings from the first Health Information National Trends Survey. Arch Intern Med. 2005; 165 (22): 2618-24.
28. Moynihan R, Bero L, Ross-Degnan D, et al., Coverage by the news media of the benefits and risks of medications. N Engl J Med. 2000 Jun 1; 342 (22): 1645-50.
29. Korownyk C, Kolber MR, McCormack J, et al., Televised medical talk shows-what they recommend and the evidence to support their recommendations: a prospective observational study. BMJ. 2014 Dec 17; 349: g7346.
30. Corbett J, Mori M., Medicine, media and celebrities: news coverage of breast cancer, 1960-1995. Journal Mass Commun Q. 1999; 76 (2): 229-49.
31. Fisher A, Martin J, Srikusalanukul W, Davis M., Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary. Clin Interv Aging. 2010; 5: 355-62.